Heavy menstrual bleeding treatment for adolescents with bleeding disorders
Official title: Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Funded at Oregon Health & Science University · NIH-11361137 · Data updated 2026-11-12
A multicenter study will compare two progestin-based treatments for heavy periods in teens and young adults with bleeding disorders to see which helps reduce bleeding and improves well-being.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 15, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $538,341 |
| NIH project number | 5R01HL173767-03 |
| Project ID | NIH-11361137 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adolescents and young adults with inherited bleeding disorders experiencing heavy menstrual bleeding who are considering progestin-based suppression and are treated at participating multi-disciplinary menstrual clinics.
✕Less likely to help
Individuals without a bleeding disorder or whose heavy menstrual bleeding is not related to BD may not benefit from this study.
What this research studies
This project targets adolescents and young adults with inherited bleeding disorders who experience heavy menstrual bleeding. It will enroll about 300 participants across several clinics and compare two hormonal options: a levonorgestrel-releasing intrauterine system (LNG-IUD) and oral norethindrone acetate. Over six months, the study will look at blood loss, quality of life, and iron storage, using a PBAC score to measure success. Results could guide personalized treatment choices to reduce bleeding and improve daily living for patients with BD. The study is designed as a pragmatic trial to reflect real-world clinical practice.
Why it matters
Potential benefit: If successful, patients could experience less heavy bleeding, better quality of life, and improved iron levels through optimized hormonal therapy.
How similar studies have gone: Prior related work supports progestin therapies for heavy menstrual bleeding, but effectiveness in adolescents with bleeding disorders is not well established, making this study innovative.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Baldwin, Maureen — Oregon Health & Science University
- Study coordinator: Baldwin, Maureen
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.